TAK vs. TEM: Takeda Pharmaceutical vs. Tempus AI Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TAK is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Takeda Pharmaceutical (TAK) has been public since January 5, 2010, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Tempus AI (TEM) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Tempus AI (TEM) has a non-negative beta of 3.34.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Takeda Pharmaceutical (TAK) reports 0.56%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Takeda Pharmaceutical (TAK) reports 0.87%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Takeda Pharmaceutical (TAK) reports 24.55%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Takeda Pharmaceutical (TAK) at -1.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Tempus AI (TEM) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics